No Data
No Data
Intratrade etc [Stocks with interesting characteristics based on volume changes]
Closing price of the stock, compared to the previous day, volume *<6190>* PXB 3,646,447,100 *<5616>* Amifuru Taiyo 84,912,672,300 *<3747>* Intertrade 441,694,784,100 *<4406>* Shin Nihon Rika 212,221,919,600 *<7162>* Astomax 25,954,996,000 *<4772>* Stream M 131,142,906,000 *<7578>* Nichiryoku 1,508,124,900 *<4331>* T&G Needs 87,479,221,600 *<41
Emerging markets stock digest: UNITED is sharply up, HOUSEI hits the daily limit.
Marked rebound. The invention related to 'Marker Peptides for the Measurement of ALT1 and ALT2' has been patented in japan, which has been well received.
Phoenix Bio--- In the second quarter, revenue declined, but demand for PXB mice increased as they transitioned from the hepatitis field to the biopharmaceutical field.
Phoenix Bio <6190> announced its consolidated financial results for the second quarter of the fiscal year ending in March 2025 (April-September 24). Revenue decreased by 10.6% year-on-year to 0.788 billion yen, operating loss was 0.098 billion yen (compared to a loss of 0.005 billion yen in the same period last year), ordinary loss was 0.123 billion yen (compared to a profit of 0.045 billion yen), and net loss attributable to parent company shareholders was 0.124 billion yen (compared to a profit of 0.027 billion yen). The demand for PXB mice is transitioning from the hepatitis field to the bio-pharmaceutical field, involving nucleic acids.
Starting lineup, RentRacs, and others.
<142A> Jingib downward revision, current fiscal year operating profit forecast 0.008 billion yen ← 0.24 billion yen <145A> Acquisition of shares of System Em's, which is engaged in development of Elise B system (web system / OA · FA system) and others, and subsidiary <149A> Sinka downward revision, current fiscal year operating profit forecast 0.073 billion yen ← 0.171 billion yen <157A> Establishment of G Monster subsidiary <195A> Rice curry performance forecast revised, current fiscal year operating profit forecast 0.125 billion yen ← 0.32 billion yen electric power A
PhoenixBio: Confirmation letter
PhoenixBio: Half Year Report - Term 24 (2024/04/01 - 2025/03/31)
No Data